Innate Pharma (IPHA) Shares Outstanding (Weighted Average) (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Shares Outstanding (Weighted Average) data on file, last reported at $109.1 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 21.78% year-over-year to $109.1 million; the trailing twelve-month figure through Dec 2025 stood at $109.1 million (up 21.78% YoY), and the FY2025 full-year result was $109.1 million, up 21.78% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $109.1 million, up from $282.99 in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $109.1 million in Q4 2025 and bottomed at $21.78 in Q2 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $83.5 million (2022), against an average of $54.3 million.
• The widest annual swing landed in 2021, when Shares Outstanding (Weighted Average) slumped 100.0%; it then jumped 23555407.09% in 2022.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $91.0 million in 2021, then decreased by 10.06% to $81.8 million in 2022, then grew by 5.78% to $86.6 million in 2023, then advanced by 3.49% to $89.6 million in 2024, then grew by 21.78% to $109.1 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $109.1 million (Q4 2025), $282.99 (Q2 2025), and $89.6 million (Q4 2024), per Business Quant data.

Peer Comparison